RPID RAPID MICRO BIOSYSTEMS, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1380106 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.1%
TTM net income YoY-16.1%
TTM EPS YoY-11.0%
Revenue 3-yr CAGR22.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-141.5%
Net margin-145.6%
FCF margin-114.8%
EBITDA margin-133.0%
Returns
ROE-141.6%
ROA-76.4%
ROIC (approx.)-135.2%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets69.6%
Debt / equity1.08x
Current ratio2.55x
Interest coverage-21.16x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $33.59M | $28.05M | $22.52M | $17.13M | $23.23M |
| R&D expense | $13.60M | $14.60M | $12.82M | $12.87M | $9.78M |
| SG&A expense | $22.75M | $21.95M | $24.94M | $26.82M | $17.89M |
| Operating income | -$47.39M | -$49.92M | -$56.56M | -$63.22M | -$47.23M |
| Interest expense | $1.09M | $40,000 | — | — | $2.65M |
| Pretax income | -$47.08M | -$46.87M | -$52.44M | -$61.38M | -$73.43M |
| Income tax | $40,000 | $22,000 | $31,000 | -$576,000 | $91,000 |
| Net income | -$47.12M | -$46.89M | -$52.47M | -$60.81M | -$73.52M |
| EBITDA | -$44.14M | -$46.56M | -$53.46M | -$60.38M | -$45.70M |
| EPS (basic) | -1.05 | -1.08 | -1.22 | -1.43 | -3.94 |
| EPS (diluted) | -1.05 | -1.08 | -1.22 | -1.43 | -3.94 |
| Weighted avg. shares (diluted) | 44.68M | 43.58M | 43.02M | 42.45M | 19.78M |
| Banking | |||||
| Net interest income | — | — | $4.21M | $1.78M | -$2.61M |
| Balance sheet | |||||
| Cash & equivalents | $20.03M | $17.28M | $24.57M | $27.35M | $178.67M |
| Short-term investments | $18.27M | $33.82M | $67.77M | $81.58M | $15.11M |
| Receivables | $3.13M | $7.52M | $5.53M | $5.37M | $5.00M |
| Inventory | $17.59M | $20.20M | $19.96M | $21.19M | $15.67M |
| Current assets | $61.17M | $80.92M | $120.42M | $138.58M | $218.12M |
| PP&E, net | $8.97M | $11.19M | $12.83M | $13.82M | $11.30M |
| Total assets | $74.85M | $98.17M | $143.45M | $190.65M | $241.17M |
| Current liabilities | $18.49M | $17.57M | $18.99M | $19.05M | $18.17M |
| Long-term debt | $18.90M | $0 | — | $0 | $0 |
| Total debt | $18.90M | $0 | — | $0 | $0 |
| Total liabilities | $41.65M | $22.82M | $25.46M | $26.48M | $20.19M |
| Shareholders' equity | $33.21M | $75.35M | $117.99M | $164.17M | $220.98M |
| Net debt | -$1.13M | -$17.28M | — | -$27.35M | -$178.67M |
| Cash flow statement | |||||
| Operating cash flow | -$31.06M | -$44.15M | -$45.08M | -$58.55M | -$54.96M |
| Capital expenditure | $850,000 | $1.36M | $1.84M | $6.74M | $3.22M |
| Free cash flow | -$31.91M | -$45.52M | -$46.93M | -$65.29M | -$58.18M |
| Investing cash flow | $14.33M | $36.66M | $42.15M | -$93.47M | -$13.29M |
| Financing cash flow | $19.77M | $203,000 | $149,000 | $693,000 | $216.75M |
| Depreciation & amortization | $3.25M | $3.36M | $3.10M | $2.84M | $1.53M |
| Stock-based compensation | $4.03M | $3.87M | $4.75M | $4.02M | $1.84M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.